Unspecified Childhood Solid Tumor, Protocol Specific Clinical Trial
Official title:
A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children With Refractory Solid Tumors
This phase I trial is studying the side effects and best dose of sunitinib in treating young patients with refractory solid tumors. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth and by blocking blood flow to the tumor.
Status | Completed |
Enrollment | 35 |
Est. completion date | |
Est. primary completion date | September 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 2 Years to 21 Years |
Eligibility |
Inclusion Criteria: - Histologically confirmed solid tumor (not required for patients with intrinsic brain stem tumors or optic pathway gliomas) - Recurrent or refractory disease - Measurable or evaluable disease - No known curative therapy or therapy proven to prolong survival with an acceptable quality of life exists - Patients with metastatic bone marrow disease are eligible but are not evaluable for hematologic toxicity - Must not be refractory to red blood cell or platelet transfusions - Primary CNS tumors or known CNS metastases allowed - Neurological deficits must have been relatively stable for = 1 week before study enrollment - No imaging evidence of prior intracranial hemorrhage - No evidence of new CNS hemorrhage on baseline MRI obtained within 14 days before study enrollment (ECHO gradient MRI sequences per institutional guidelines required for evaluation of CNS hemorrhage) - The presence of small punctuate CNS hemorrhage on these scans will exclude a patient from participation - No known bone marrow metastatic disease - No tumors involving the pleural surface - Karnofsky performance status (PS) 50-100% (> 10 years of age) OR Lansky PS 50-100% (= 10 years of age) - Absolute neutrophil count = 1,000/mm³* - Platelet count = 100,000/mm³ (transfusion independent)* - Hemoglobin = 8.0 g/dL (transfusions allowed)* - Creatinine clearance or radioisotope glomerular filtration rate = 70 mL/min OR creatinine based on age/gender as follows: - No greater than 0.8 mg/dL (2 to 5 years of age) - No greater than 1 mg/dL (6 to 9 years of age) - No greater than 1.2 mg/dL (10 to 12 years of age) - No greater than 1.5 mg/dL (male) OR 1.4 mg/dL (female) (13 to 15 years of age) - No greater than 1.7 mg/dL (male) OR 1.4 mg/dL (female) (= 16 years of age) - Bilirubin = 1.5 times upper limit of normal (ULN) - ALT and AST = 2.5 times ULN (= 5 times ULN for liver metastases) - Albumin = 2 g/dL - LVEF or shortening fraction normal - Corrected QT interval = 450 msec - Amylase = 1.5 times ULN - Lipase = 1.5 times ULN - Body surface area = 0.5 m² (= 0.4 m² for part B) - Blood pressure within ULN - Not pregnant or nursing - Fertile patients must use effective contraception - No uncontrolled infection - Able to swallow sunitinib malate capsules (part A only) - No pre-existing thyroid abnormality (hyper- or hypothyroidism) with unstable thyroid function - No prior CNS hemorrhage - No history of allergic reaction attributed to sunitinib malate or component of sunitinib malate capsules - No allergy to both applesauce and yogurt (part B only) - Recovered from prior therapy - No prior sunitinib malate - No prior anthracycline (any dose) - No prior radiotherapy to a radiation field that included the heart(including total body or craniospinal irradiation) - At least 3 months since prior stem cell transplantation or rescue (without total-body irradiation) and no evidence of graft-vs-host disease - At least 2 weeks since prior local, palliative, small-port radiotherapy (at least 6 months for radiation to = 50% of pelvis) - At least 6 weeks since other prior substantial bone marrow radiotherapy - At least 3 weeks since prior myelosuppressive therapy (6 weeks for nitrosoureas) - At least 1 week since prior antineoplastic biologic agents - At least 1 week since prior and no concurrent hematopoietic growth factors - At least 12 days since prior and no concurrent CYP3A4 inducers, including any of the following: - Rifampin - Rifabutin - Carbamazepine - Phenobarbital - Phenytoin - Hypericum perforatum (St. John's wort) - Efavirenz - Tipranavir - At least 7 days since prior and no concurrent CYP3A4 inhibitors, including any of the following: - Azole antifungals (e.g., itraconazole or ketoconazole) - Clarithromycin - Erythromycin - Diltiazem - Verapamil - HIV protease inhibitors (e.g., indinavir, saquinavir, ritonavir, atazanavir, or nelfinavir) - Delavirdine - No more than 1 concurrent antihypertensive agent - No concurrent major surgery - No concurrent antithrombotic or antiplatelet agents, including any of the following: - Warfarin - Heparin - Low molecular weight heparin - Acetylsalicylic acid (aspirin) - Ibuprofen - Other nonsteroidal anti-inflammatory drugs - No concurrent medication for the treatment of hypertension - No other concurrent investigational drugs - No other concurrent anticancer agents, including chemotherapy, radiotherapy, immunotherapy, or biologic therapy |
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Centre Hospitalier Universitaire Sainte-Justine | Montreal | Quebec |
Canada | Hospital for Sick Children | Toronto | Ontario |
United States | C S Mott Children's Hospital | Ann Arbor | Michigan |
United States | University of Alabama at Birmingham | Birmingham | Alabama |
United States | Dana-Farber Cancer Institute | Boston | Massachusetts |
United States | Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio |
United States | University of Texas Southwestern Medical Center | Dallas | Texas |
United States | Baylor College of Medicine | Houston | Texas |
United States | Columbia University Medical Center | New York | New York |
United States | Childrens Hospital of Orange County | Orange | California |
United States | Children's Hospital of Philadelphia | Philadelphia | Pennsylvania |
United States | Children's Hospital of Pittsburgh of UPMC | Pittsburgh | Pennsylvania |
United States | Washington University School of Medicine | Saint Louis | Missouri |
United States | UCSF-Mount Zion | San Francisco | California |
United States | University of California San Francisco Medical Center-Parnassus | San Francisco | California |
United States | Seattle Children's Hospital | Seattle | Washington |
United States | Children's National Medical Center | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | MTD and recommended phase II dose | MTD will be the maximum dose at which fewer than one-third of patients experience dose-limiting toxicity (DLT). | During course 1 of therapy | Yes |
Primary | Adverse events as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 | Weekly during course 1, assessed up to 35 days | Yes | |
Primary | Pharmacokinetics of sunitinib malate using liquid spectrometry/mass spectroscopy methods | At baseline and days 1, 7, 14, 21, and 28 of course 1 | No | |
Primary | Tolerability and pharmacokinetic profile of capsule contents sprinkled over applesauce or yogurt | At baseline and days 1, 7, 14, 21, and 28 of course 1 | No | |
Secondary | Correlative studies | The laboratory, radiology, and pathology correlative studies are largely expected to be exploratory. Mean and median values will be reported at each time point for circulating endothelial cells, monocyte count, plasma angiogenic markers, and DCE-MRI vascular permeability. Depending on the distribution of data, either the paired t-test or Wilcoxon signed rank test will be used to evaluate for statistically significant changes in these markers from pre-treatment to post-treatment. | Days 1 and 28 of course 1 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT01164163 -
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
|
Phase 1 | |
Completed |
NCT00985868 -
AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors
|
Phase 1 | |
Terminated |
NCT00949117 -
Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer
|
Phase 2 | |
Completed |
NCT00253474 -
PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma
|
Phase 1 | |
Completed |
NCT00281944 -
Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT00084695 -
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
|
Phase 2 | |
Completed |
NCT00053963 -
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
|
Phase 1 | |
Completed |
NCT00003070 -
Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer
|
Phase 3 | |
Completed |
NCT00004212 -
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT00004005 -
Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin
|
Phase 2 | |
Completed |
NCT00003754 -
Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers
|
Phase 2 | |
Completed |
NCT00016861 -
Irinotecan in Treating Children With Refractory or Progressive Solid Tumors
|
Phase 1 | |
Completed |
NCT00003173 -
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
|
Phase 2 | |
Recruiting |
NCT00898794 -
Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer
|
N/A | |
Terminated |
NCT00429702 -
Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy
|
Phase 2 | |
Completed |
NCT00459238 -
Telephone-Based Cancer Education With or Without Telephone-Based Counseling in Young Participants
|
N/A | |
Completed |
NCT00138216 -
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
|
Phase 1 | |
Completed |
NCT00070473 -
Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors
|
Phase 1 | |
Terminated |
NCT00176540 -
Dextromethorphan in Treating Patients With Fatigue Caused by Cancer
|
N/A |